Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
102.00    2.10 (2.10%)
Bid:
101.00
Ask:
102.00
Spread: 1.00 (0.99%)
Market Cap: £620.36m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Dividend Declaration

5 Jul 2016 18:33

BACIT LIMITED - Dividend Declaration

BACIT LIMITED - Dividend Declaration

PR Newswire

London, July 5

BACIT Limited (the "Company")

(a closed-ended collective investment scheme established as a company with limited liability under the laws of Guernsey with registered number 55514)

2016 Dividend5 July 2016

The Board of the Company is pleased to announce a dividend equivalent to 2.20 pence per ordinary share for the year ended 31 March 2016 (the “2016 Dividend”). The 2016 Dividend will be paid on 19 August 2016 to holders of ordinary shares recorded on the register as at the close of business on 15 July 2016.

The Board has determined that the 2016 Dividend will be paid to the Qualifying Shareholders (as defined below) in the form of new ordinary shares unless those shareholders elect to receive the dividend in cash instead. The number of new shares that each Qualifying Shareholder will receive in payment of the 2016 Dividend will be determined by multiplying the number of existing shares held by the shareholder on the record date by the cash equivalent amount of the 2016 Dividend per share and dividing the resulting number by the net asset value per share of the Company as at 30 June 2016, and then rounding the result down to the nearest whole number. Fractions of new shares will not be issued and cash that otherwise would have been applied by the Company in paying up those fractions will be retained by the Company.

A “Qualifying Shareholder” is a shareholder who is not located in, or with a registered address in, or a citizen of any of the United States, Australia, Canada, Japan, South Africa or any other jurisdiction in respect of which the offer of new shares would or may be unlawful.

Shareholders who are not Qualifying Shareholders will receive the 2016 Dividend in cash. In addition, Qualifying Shareholders can elect to receive the 2016 Dividend in cash. A circular and form of election will be sent to shareholders during the week commencing 11 July 2016. Qualifying Shareholders who wish to receive the 2016 Dividend in cash should complete and return the form of election by 5.00pm on 3 August 2016.

Timetable:

Posting of Circular and Forms of ElectionExpected during the week commencing 11 July 2016
Shares quoted ex-dividend14 July 2016
Record date for dividend15 July 2016
Announcement of the 30 June 2016 NAVExpected during the week commencing 25 July 2016
Final date for receipt by the Receiving Agent of forms of election by Qualifying Shareholders who wish to receive cash5 p.m. on 3 August 2016
Dividend payment date19 August 2016
Shares to be issued and cash to be paid to shareholders who have opted for the cash dividend19 August 2016

In compliance with LR 9.6.1, copies of the following documents will be submitted to the National Storage Mechanism at the same time as they are issued and will be available for inspection at www.hemscott.com/nsm.do:

1.2016 Dividend Circular

2.Form of election

Enquiries:

Company website: www.bacitltd.com

Northern Trust International Fund Administration Services (Guernsey) Limited Martin Bourgaize

+44 (0) 1481 745819

meb16@ntrs.com

Page 2

Date   Source Headline
12th May 20224:00 pmRNSAutolus to present clinical data at EHA Congress
11th May 20227:00 amRNSFreeline reports Q1 2022 Financial Results
10th May 20221:02 pmRNSAchilles reports Q1 2022 Financial Results
5th May 202212:05 pmRNSAutolus Reports Q1 2022 Financial Results
28th Apr 20227:00 amRNSSyncona invests in £75.5 million OMass Series B
11th Apr 20227:00 amRNSAnaveon announces initial clinical data
4th Apr 202212:34 pmRNSDirector/PDMR Shareholding
1st Apr 20227:00 amRNSFreeline reports Full Year 2021 Financial Results
24th Mar 20224:11 pmRNSHolding(s) in Company
23rd Mar 20228:30 amRNSFreeline enters into ADS purchase agreement
11th Mar 20227:00 amRNSFreeline registered direct offering
10th Mar 202212:05 pmRNSAutolus Reports Full Year 2021 Financial Results
9th Mar 20224:39 pmRNSDirector/PDMR Shareholding
9th Mar 20223:09 pmRNSHolding(s) in Company
7th Mar 20225:29 pmRNSDirector/PDMR Shareholding
1st Mar 202212:56 pmRNSAchilles reports Full Year 2021 Results
18th Feb 20227:00 amRNSCompletion of sale of Gyroscope Therapeutics
8th Feb 202212:05 pmRNSFreeline presents data in Fabry disease
31st Dec 20217:00 amRNSDirectorate Change
22nd Dec 20217:00 amRNSGyroscope to be acquired for up to $1.5 billion
16th Dec 20217:00 amRNSSyncona cornerstones Anaveon Series B
14th Dec 20217:00 amRNSFreeline reports 2022 priorities and guidance
13th Dec 20212:05 pmRNSFreeline presents data in haemophilia B
13th Dec 202112:05 pmRNSAutolus presents positive AUTO1 (obe-cel) data
29th Nov 20217:00 amRNSSyncona co-leads Series B financing in Quell
22nd Nov 20217:00 amRNSSyncona appoints new Directors
12th Nov 20211:56 pmRNSAchilles Presents Data at the SITC Annual Meeting
11th Nov 20217:00 amRNSHalf-year Report
10th Nov 20217:00 amRNSFreeline reports new data and 3rd Quarter Results
9th Nov 20211:31 pmRNSAchilles reports Third Quarter Financial Results
8th Nov 20211:05 pmRNSGyroscope Announces Sanofi Equity Investment
8th Nov 20217:00 amRNSBlackstone Life Science to invest $250m in Autolus
3rd Nov 202111:07 amRNSSyncona leads $87 million financing of Clade
3rd Nov 202111:05 amRNSAutolus reports Q3 2021 Financial Results
26th Oct 20217:00 amRNSNotice of Results
30th Sep 20213:59 pmRNSGyroscope announces additional positive data
17th Aug 20217:00 amRNSFirst Quarter Update
16th Aug 202112:07 pmRNSFreeline Reports Executive Change and Q2 Results
10th Aug 202112:05 pmRNSAchilles reports Second Quarter 2021 Results
5th Aug 202112:05 pmRNSAutolus reports Q2 2021 Financial Results
3rd Aug 20211:16 pmRNSResult of AGM - Replacement
3rd Aug 202112:32 pmRNSResult of AGM
30th Jul 202112:17 pmRNSTotal Voting Rights
27th Jul 20212:41 pmRNSHolding(s) in Company
15th Jul 202112:57 pmRNSIssue of shares pursuant to incentive scheme
1st Jul 202111:54 amRNSPublication of 2021 Annual Report & Notice of AGM
24th Jun 20217:00 amRNSAnaveon doses first patient in Phase I/II study
17th Jun 20217:00 amRNSFinal Results
17th Jun 20217:00 amRNSSyncona announces expansion of leadership team
11th Jun 202112:05 pmRNSAutolus to present additional data in AUTO1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.